Expression data in sera from patients with anti-tuberculosis drug-induced liver injury

The pathogenesis of liver damage induced by anti-tuberculosis drugs is not fully understood, andcurrently, there is no clinically useful biomarker for early diagnosis and treatment.By comparing the differences in the expression of global gene transcripts in the serum of patients with and without anti-tuberculosis drugs induced liver injury, dysregulation genes not only provides a basis for studying pathogenesis, but also provides important information to find new targets for diagnosis and treatment of disease. We used microarrays to detail the global programme of gene expression in sera underlying anti-tuberculosis drug-induced liver injury and identified distinct classes of transcript during this process. sera from patients with anti-tuberculosis drug-induced liver injury were selected for RNA extraction and hybridization on Affymetrix microarrays. We examined blood samples from 4 patients, in order to reduce the age , gender and the interference of the treatment with the drugs, we matched the blood samples of 4 patients with comparable TB treatment as controls. To that end, diagnostic criteria was in keeping with the Guidelines for the diagnosis and treatment of anti-tuberculosis drug-induced liver injury by the Chinese Medical Association Tuberculosis Branch (2019 edition). The laboratory test indicators used are serum biochemical results: Alanine aminotransferase (ALT) ≥3 times Upper limit of normal value (ULN) and/or total bilirubin≥2 times ULN; or Aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total Bilirubin are elevated at the same time, in addition at least one item is ≥2 times ULN.